“We are not doing too bad in Denmark”
The US biotech industry is probably the most important driving force on the global market. But are Danish companies really taking advantage of that. No, says top-exec Jan Leschly. But the biotech experts of the Medwatch Panel disagree.
Danish biotech companies have one major problem. Their research is top-shelf, but we have a hard time continuing the development of the products and bringing them through clinical trials, says Jan Leschly, partner in the American venture fund Care Capital. Many biotech companies underestimate the value of bringing in outside expertise to attract US capital, and generally speaking there is not enough focus on the US, he believes.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
”We are in desperate need of financing options”
For abonnenter
